川芎嗪对人肝癌HepG-2细胞体外侵袭和迁移的影响

doi:10.3969/j.issn.1672-5069.2018.01.031

Abstract

Sun Xiao, Yin Zhongpu, Yin Hongmei. Effects of tetramethylpyrazine on invasion and migration of HepG-2 cells in vitro[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 118-120.

[1] 徐教邦,卜庆敖,王希超,等. 直径≤5 cm肝癌手术切除与射频消融术后乙型肝炎病毒激活率的比较. 中华肝胆外科杂志,2016,22（9）:602-606.
[2] 吴黎雳,宦宏波,温旭东,等. 迷走神经递质P物质对人类肝癌细胞侵袭转移能力的影响及其分子机制. 第三军医大学学报,2015,37（7）:643-648.
[3] 徐丽君,吴南丹,杨颖,等. 川芎嗪抑制人视网膜母细胞瘤WERI-Rb1细胞增殖的机制研究. 广东医学,2016,37（18）:2721-2724.
[4] 王博,史本康. 川芎嗪经超声电导前列腺治疗仪直肠给药治疗Ⅲ型慢性前列腺炎效果观察. 山东医药,2017,57（2）:85-86.
[5] 霍梦琪,张燕玲,郑世超,等. 基于共表达蛋白相互作用网络探讨川芎嗪治疗冠心病的机制. 北京中医药大学学报,2016,39（12）:989-997.
[6] 何光志,邓树轩,何前松,等. 皂角刺总黄酮对肝癌HepG2细胞增殖、凋亡和侵袭能力影响的实验研究. 湖南师范大学自然科学学报,2012,35（1）:77-81.
[7] Ito H,Tanaka S,Akiyama Y,et al. Dominant expression of DCLK1 in human pancreatic cancer stem cells accelerates tumor invasion and metastasis. Plos One,2016,11（1）:e0146564.
[8] Lee KR,Kozukue N,Han JS,et al. Glycoalkaloids and metabolites inhibit the growth of human colon（HT29） and liver （HepG2） cancer cells. J Agricult Food Chem,2004,52（10）:2832-2839.
[9] 吴婷婷,丁玉勇. 川芎嗪生物活性的研究进展. 食品研究与开发,2016,37（6）:212-217.
[10] 牛媛,王成,张晓燕,等. 川芎嗪对人肺腺癌A549细胞增殖、迁移和侵袭的作用与机制. 现代肿瘤医学,2016,24（10）:1509-1512.
[11] Fidler I J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res,2016,38（9）:2651-2660.
[12] 毕蕾,颜晓静,杨烨,等. 川芎嗪对肝癌HepG2细胞迁移、侵袭和细胞骨架的影响. 中国药理学通报,2016,32（2）:194-198.
[13] 孙宇,单路娟,刘越坚,等. 华蟾素注射液对人肝癌HepG-2细胞增殖及凋亡的影响. 中国肿瘤,2010,19（6）:410-413.
[14] Kolude B,Adisa A O,Lawal A O,et al. Stoichiometric expression of MMP-2/TIMP-2 in benign and malignant tumours of the salivary gland. Tumor Biol,2015,36（4）:1-7.

Effects of tetramethylpyrazine on invasion and migration of HepG-2 cells in vitro

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics

Comments

[1]	Yan Ruibin, Ma Shumei, Zhuo Ma, et al. Significance of portal vain parameters by ultrasonography and serum MMP-2 and TIMP-2 detection in evaluation of liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 506-509.
[2]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[3]	Zheng Xu，Qiu Xiong，Shao Zeyong，Luo Wenjie, Tang Shixiao. Changes of serum CEMIP, CA19-9 and CA242 levels in patients with pancreatic cancer and their clinical significance [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 280-284.
[4]	Yi Weimin, Peng Chuang, Li Ou, et al.. Expression of CD147 and its clinical significance in patients with intrahepatic cholangiocarcinoma complicating intrahepatic bile duct stones [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 97-100.
[5]	Ge Hongyan，Jiang Hao.. Effect of Qinggan Jiuweisan，a Mongolia herbal medicine，on serum TIMP-1 levels in treatment of patients with alcoholic hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 720-721.
[6]	Li Ziqiong, Mu Nila, Gao Feng. Inhibiting effects of antisense transforming growth factor β type I receptor and antisense TIMP-1 on experimental hepatic fibrosis in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 67-70.
[7]	Li Caidong, Yang Yongwei, Tian Pengfei, et al. Changes of serum macrophage migration inhibitory factor, IL-17 and IL-10 levels in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 71-73.
[8]	HU Xudong，CHENG Hailin，TIAN Dean，et al.. The effect of interferon-αon hepatic fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(4): 262-264.
[9]	CHEN Hao，LI Jiansheng，JIA Weidong，et al.. Serum levels of extracellular matrix protein 1，MMP-9 and VEGF in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(6): 424-427.